Tetsuro Kikuchi
Tetsuro Kikuchi, Osaka JP
Patent application number | Description | Published |
---|---|---|
20110038958 | USE OF CANNABINOIDS IN COMBINATION WITH AN ANTI-PSYCHOTIC MEDICAMENT - The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication. | 02-17-2011 |
20120165402 | USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY - This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD. | 06-28-2012 |
20130059018 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER - This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon. | 03-07-2013 |
20140120185 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER - The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination. | 05-01-2014 |
20150086653 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER - This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon. | 03-26-2015 |
20150335590 | USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY - This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD. | 11-26-2015 |
Tetsuro Kikuchi, Tokushima-Shi JP
Patent application number | Description | Published |
---|---|---|
20080318972 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 12-25-2008 |
20090012098 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 01-08-2009 |
20090181978 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 07-16-2009 |
20100273810 | METHOD OF TREATING COGNITIVE IMPAIRMENTS AND SCHIZOPHRENIAS - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 10-28-2010 |
20110281889 | 5-HT1A Receptor Subtype Agonist - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 11-17-2011 |
20110294821 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 12-01-2011 |
20120088777 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 04-12-2012 |
20120095018 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 04-19-2012 |
20120172373 | METHOD OF TREATING COGNITIVE IMPAIRMENTS AND SCHIZOPHRENIAS - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 07-05-2012 |
20120238584 | 5-HT1A receptor subtype agonist - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 09-20-2012 |
20130296336 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 11-07-2013 |
20150174125 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 06-25-2015 |
Tetsuro Kikuchi, Nishio-Shi JP
Patent application number | Description | Published |
---|---|---|
20090274935 | Fuel Cell System Designed to Ensure Stability of Operation - A fuel cell control system is provided which is designed to ensure the stability of operation of a fuel cell stack. The system includes a magnetic sensor and a controller. The magnetic sensor works to measure a change in magnetic flux density of magnetic field produced by an electric current as generated by electrochemical reaction taken place in each of fuel cells. The controller is designed to analyze the change in magnetic flux density measured by the magnetic sensor to specify the cause and location resulting in a drop in ability of the fuel cell stack to generate electricity which is to occur partially in the fuel cell stack. The controller takes a predetermined measure to control the operation of the fuel cell stack for eliminating the drop in ability of the fuel cell stack to generate the electricity. | 11-05-2009 |
Tetsuro Kikuchi, Iwate JP
Patent application number | Description | Published |
---|---|---|
20090114404 | Sprinkler head - The present invention is directed to overcome such a problem associated with a sprinkler head made of In-based alloy with no use of Pb or Cd that in contradiction with the fact that a testing temperature in a strength test of a sprinkler head is proximal to a melting temperature of a solder alloy used in a heat-sensitive decomposition structure of the sprinkler head, and therefore a good creeping property over a higher temperature zone in which a sprinkler is activated is required, typically, the sprinkler head made of the In-based alloy with no use of Pb or Cd could not achieve the creeping property over the higher temperature zone in which the sprinkler is activated as favorably as any conventional sprinkler head using Pb or Cd could do, and could occasionally end in failure in a durability test. | 05-07-2009 |
20090148338 | Alloy for a Fusible Plug and a Fusible Plug - Problems: A conventional alloy for a fusible plug contained harmful elements such as Cd and Pb, and there was a concern of pollution by these harmful elements. The present invention provides a fusible plug which does not contain the harmful elements Cd and Pb, with which the alloy is not forced out of the fusible plug even when used for long periods as a safety device for refrigeration equipment, and which has a strong mechanical strength such as creep strength. | 06-11-2009 |
Tetsuro Kikuchi, Tokyo JP
Patent application number | Description | Published |
---|---|---|
20110155265 | VALVE MECHANISM OPENED IN RESPONSE TO EXTREMELY HIGH TEMPERATURE - Provided is a valve mechanism which has a simple configuration, being available for a type having a large bore diameter, and being able to be opened in response to extremely high temperature to supply fire-fighting water or cooling water. There is provided a valve mechanism opened in response to extremely high temperature, the valve mechanism including: a cylindrical body that is attached to an end of a supply pipe connected to a water source; a stopper that blocks a channel inside the body; a support that is disposed inside the body and that supports the stopper by pressing the stopper to a side of the supply pipe; a locking unit that serves to lock the support in a normal state and that unlocks the support in the case of extremely high temperature; and a heat sensitive section that releases the locking unit in the case where temperature of environment is increased to an extremely high level. | 06-30-2011 |
Tetsuro Kikuchi, Osaka-Shi JP
Patent application number | Description | Published |
---|---|---|
20140107192 | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN - The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts. | 04-17-2014 |
20140378539 | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN - The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts. | 12-25-2014 |
Tetsuro Kikuchi, Tokushima JP
Patent application number | Description | Published |
---|---|---|
20140221388 | CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS - The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder. | 08-07-2014 |
Tetsuro Kikuchi, Miyagi JP
Patent application number | Description | Published |
---|---|---|
20150340243 | PLASMA ETCHING METHOD - In a plasma etching method, with respect to a substrate to be processed, which has a base layer, a silicon oxide film, and an etching mask formed in this order, the etching mask having an etching pattern formed thereon and being formed of polysilicon, a silicon-containing deposit is deposited on a surface of the etching mask using a plasma generated from a processing gas, while applying a negative direct current voltage to an upper electrode formed of silicon. Furthermore, in the plasma etching method, the silicon oxide film is etched using plasma generated from a first CF-based gas using, as a mask, the etching mask having the silicon-containing deposit deposited thereon. | 11-26-2015 |